Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Global estimates indicated 2.3 million new cases of breast cancer in 2020, contributing to nearly 12% of all new cancer cases, with 685 000 deaths in the same year.1 Breast cancer detection has increased due to improvements in screening techniques. The mortality rate […]

Non-oncogene-addicted metastatic non-small-cell lung cancer

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Pathological diagnosis and subtyping are carried out according to the World Health Organization (WHO) guidelines download

Oncogene-addicted metastatic non-small-cell lung cancer

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Biomarker testing is essential to identify subgroups of NSCLC with oncogenic drivers that can be therapeutically targeted. These drivers are mainly found in lung adenocarcinomas (LUADs) download

ESMO Patient Guide Series based on the ESMO Clinical Practice Guidelines

ESMO Patient Guide Series based on the ESMO Clinical Practice Guidelines  This guide has been prepared to help you, as well as your friends, family and caregivers, better understandnon-small-cell lung cancer (NSCLC) and its treatment. It contains information on the different subtypes ofNSCLC, the causes of the disease and how it is diagnosed, up-to-date guidance […]